Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Orphan Designation A Game-Changer For DARA

Last November 2012, DARA Biosciences (DARA) announced it has submitted an application to the U.S. FDA requesting Orphan Drug designation on KRN5500 for the treatment of chronic chemotherapy-induced peripheral neuropathy (CCIPN). It's been over a year since that submission, and that may scare some investors into believing all hope is lost. After all, the FDA's own target for responding to Orphan Drug applications is 75 days, and so far in 2013 91% have been under 90 days. But we know for a fact that DARA and the FDA have been going back and forth on the application. We believe this is because of the overall size of the CCIPN market.

We discuss this below, and conclude that the

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details